Clinical trials: Progressive Disease
Neurodegenerative Diseases, Parkinson Disease
Neurodegenerative Diseases Progression Markers (MARKERS-NDD)
MARKERS-NDD is a prospective, observational, longitudinal study, which aims to collect data from patients affected by neurodegenerative diseases (NDD) followed longitudinally for routine examinations performed as part of normal…
- Conditions
- Neurodegenerative Diseases, Parkinson Disease, Synucleinopathies, Lewy Body Disease
- Trial name
- MARKERS-NDD (NCT06596746)
- Testing
- Observation
- Where
- Italy
- Volunteers
- 600 people
- Sponsor
- Casa di Cura San Raffaele Cassino
UC (Urothelial Cancer)
Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo in Recurrent or Progressive Metastatic Urothelial Carcinoma
The purpose of this study was to evaluate the efficacy and safety of pembrolizumab + epacadostat vs pembrolizumab + placebo as a treatment for recurrent or progressive metastatic urothelial carcinoma in patients who have failed a…
- Trial name
- NCT03374488
- Testing
- Pembrolizumab, Epacadostat
- Where
- 135 sites in United States, Australia and 16 more
- Volunteers
- 84 people
- Sponsor
- Incyte Corporation
Primary Progressive Aphasia
Stimulating the Aging Brain Using Brain and Sensory Stimulation
The goal of this project is to investigate whether transcranial electrical stimulation and sensory stimulation affect language outcomes in individuals with primary progressive aphasia (PPA).
- Trial name
- StAB (NCT07650188)
- Testing
- tACS or multisensory stimulation
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Medical College of Wisconsin
Multiple Myeloma
MMVAR - Velcade: Study of Velcade for the Treatment of Myeloma Patients After Autologous Transplantation
This is an international study in adult patients diagnosed with multiple myeloma who have already received at least one autologous stem cell transplantation and who have responded but later progressed, or relapsed, at least one…
- Trial name
- NCT00256776
- Testing
- Velcade (Bortezomib), Thalidomide, Dexamethasone
- Where
- 81 sites in Austria, Belgium and 8 more
- Volunteers
- 269 people
- Sponsor
- European Society for Blood and Marrow Transplantation
Progression-free Survival Was Defined From Date of Surgery to Disease Progression Post-surgery or Death or Last Follow-up, Overall Survival Was Defined as Time From Surgery to Death From Any Cause or Last Follow-up
Observational, Bivariate Analysis of Clinical Big Data in Patients With Cervical Cancer
This is a large non-interventional observational bidirectional study planned to collect clinically relevant data and prognostic follow-up information of patients with cervical cancer who were seen at our center from 2010.01.01 to…
- Trial name
- NCT06480617
- Where
- China
- Volunteers
- 3,000 people
- Sponsor
- Anhui Provincial Hospital
Progressive Supranuclear Palsy
Continuously Infused Recombinant-Methionyl Human Glial Cell Line-Derived Neurotrophic Factor (GDNF) to Treat Progressive Supranuclear Palsy
This study will examine the safety and effectiveness of an experimental drug called GDNF delivered through an investigational device to treat progressive supranuclear palsy (PSP).
- Trial name
- NCT00005903
- Testing
- GDNF & Synchro Med Infusion System
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Primary Dysmenorrhea
Virtual Reality-Based Relaxation and Exergaming vs. Traditional Relaxation for Primer Dysmenorrhea
The goal of this clinical trial is to investigate the acute effects of virtual reality-based relaxation (immersive VR relaxation) and exergaming (non-immersive VR) compared to traditional Jacobson's relaxation on symptoms of…
- Trial name
- NCT06728306
- Testing
- Immersive Virtual Reality-Based Relaxation, Non-immersive VR-Based Exergaming, Jacobson's Relaxation
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 43 people
- Sponsor
- Trakya University
Amyotrophic Lateral Sclerosis
An Open-Label Extension for the Phase 2 Study in Early Symptomatic Amyotrophic Lateral Sclerosis Patients on Stable Background Therapy to Assess Bioenergetic Catalysis With CNM-Au8 to Slow Disease Progression in ALS
This is an optional open-label extension to participants that have completed the clinical trial CNMAu8.205.
- Trial name
- NCT05299658
- Testing
- CNMAu8
- Where
- 2 sites in Australia
- Volunteers
- 40 people
- Sponsor
- Clene Nanomedicine
FSHD, FSHD1
Phase 1/2 Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)
A Randomized, Double-blind, Placebo-controlled, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of AOC 1020 Administered Intravenously to Participants with…
- Conditions
- FSHD, FSHD1, FSHD2, FMD
- Trial name
- FORTITUDE (NCT05747924)
- Testing
- AOC 1020
- Where
- 17 sites in United States, Canada and 1 more
- Volunteers
- 90 people
- Sponsor
- Avidity Biosciences, Inc.
Progressive Muscle Relaxation Technique
Investigation of The Effect of Progressive Muscle Relaxation Technique in Sedentary Obese Women
Obesity is a major public health problem that reduces quality of life and increases the risk of many chronic diseases. Its global prevalence continues to rise, and it is estimated that approximately 18 percent of men and 21…
- Trial name
- NCT07244718
- Testing
- Control, Music-Assisted Progressive Muscle Relaxation
- Where
- Turkey (Türkiye)
- Volunteers
- 20 people
- Sponsor
- Pamukkale University
Ischemic Stroke, Acute, Tumor Progression
Predictive Value of Human Microbiome and Serological Markers for Clinical Outcome of AIS With Active Cancer
Explore with active cancer patients with acute ischemic stroke in the human body characteristic microorganism disorder to clinical prognosis of the predictive value of the secondary objective: to observe with active cancer…
- Trial name
- NCT05553990
- Testing
- intestinal flora disturbance
- Where
- China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Nanfang Hospital, Southern Medical University
Pulmonary Arterial Hypertension
A Study to Assess Whether Macitentan Delays Disease Progression in Children With Pulmonary Arterial Hypertension (PAH)
This is a prospective, multicenter, open-label, randomized, controlled, parallel Phase 3 study with an open-label single-arm extension period to evaluate pharmacokinetics (PK), safety and efficacy of macitentan in children with…
- Trial name
- TOMORROW (NCT02932410)
- Testing
- Macitentan, Standard-of-care
- Where
- 85 sites in United States, Australia and 21 more
- Volunteers
- 165 people
- Sponsor
- Actelion
Breast Cancer, Breast Carcinoma
A Study of 1 8F-FDHT PET/MRIScans in Women With Breast Cancer
The purpose of this study is to see whether 18F-FDHT PET/MRI scans are an effective way of identifying AR-positive breast cancer.
- Conditions
- Breast Cancer, Breast Carcinoma, Metastatic Breast Cancer, Metastatic Breast Carcinoma
- Trial name
- NCT06145399
- Testing
- 18F-FDG PET/CT, [18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone PET Imaging, 18F-FDHT
- Sponsor
- Memorial Sloan Kettering Cancer Center
Osteosarcoma
A Phase II Study of Oral Cyclophosphamide and Sirolimus (OCR) in Advanced Sarcoma
The purpose of this Phase II study will assess the effectiveness of the combination of oral cyclophosphamide and sirolimus in sarcoma patients with relapsed or widespread disease who cannot be cured by surgery, radiation or…
- Trial name
- OCR (NCT00743509)
- Testing
- Cyclophosphamide and Sirolimus
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- University of Michigan Rogel Cancer Center
Pulmonary Fibrosis
Exhaled Breath Analysis Using eNose Technology as a Biomarker for Diagnosis and Disease Progression in Fibrotic ILD
The ILDnose study a multinational, multicenter, prospective, longitudinal study in outpatients with pulmonary fibrosis. The aim is to assess the accuracy of eNose technology as diagnostic tool for diagnosis and differentiation…
- Trial name
- ILDnose (NCT04680832)
- Testing
- Electronic nose
- Where
- 5 sites in Australia, France and 3 more
- Volunteers
- 600 people
- Sponsor
- Erasmus Medical Center
Glioblastoma, Astrocytoma, Grade IV
A Study to Evaluate the Safety, Tolerability and Immunogenicity of EGFR(V)-EDV-Dox in Subjects With Recurrent GBM
The purpose of the Cerebral EDV study is to determine the safety and tolerability of EGFR(V)-EDV-Dox in order to establish the best dose level to be used in future studies.
- Trial name
- CerebralEDV (NCT02766699)
- Testing
- EGFR(V)-EDV-Dox
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- Engeneic Pty Limited
Acute Myeloid Leukemia
Fractionated Gemtuzumab Ozogamicin Followed by Non-engraftment Donor Leukocyte Infusions for Relapsed/Refractory Acute Myeloid Leukemia
This study includes patients with relapsed acute leukemia who have previously been treated with standard treatment that is still present and there is no curative treatment option available.
- Trial name
- NCT03374332
- Testing
- Gemtuzumab Ozogamicin (GO), Donor Leukocytes
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Brown University
Hepatitis C, Chronic, Disease Progression
Prospective Observational Study of Disease Progression in Chronic Hepatitis C
The purpose of this study is to determine the progression of chronic hepatitis C patients infected by paid plasma donation,and explore the possible pathogenic mechanisms of disease progression in chronic hepatitis C.
- Conditions
- Hepatitis C, Chronic, Disease Progression, Liver Cirrhosis
- Trial name
- NCT02011932
- Volunteers
- 133 people, healthy volunteers welcome
- Sponsor
- Beijing YouAn Hospital
Recurrent Meningioma
RYZ101 for the Treatment of Progressive or Recurrent Intracranial Meningioma
This phase I/II tests the safety, side effects, best dose and how well giving RYZ101 works for the treatment of patients with intracranial meningioma that is growing, spreading, or getting worse (progressive) or that has come…
- Trial name
- NCT07150806
- Testing
- Actinium Ac 225 DOTATATE RYZ101, Biospecimen Collection, Computed Tomography
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Joshua Palmer
Effect of Drugs, Progression
Famitinib Plus Camrelizumab & Famitinib Alone & Famitinib Plus Ifosfamide in Advanced Osteosarcoma
Results of previous study showed high objective response but short-term activity of anti-angiogenesis tyrosine kinase inhibitors in advanced osteosarcoma.
- Conditions
- Effect of Drugs, Progression, Pediatric Cancer
- Trial name
- NCT04044378
- Testing
- Famitinib, Ifosfamide, Camrelizumab
- Where
- China
- Sponsor
- Peking University People's Hospital